ArticleBMC cancer2025
Uncovering rare somatic variants in olfactory receptor genes in Pakistani triple-negative breast cancer patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dissecting cancer in a non-mammalian model: genomic insights from lemon frost geckos.BMC biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a heterogeneous illness in terms of histologic variants, natural history of disease, clinical behaviour, and response to therapy. Triple-negative breast cancer (TNBC) is a biologically aggressive tumour with the worst prognosis among all subtypes, owing to higher grade and high proliferation capacity, and, restricted therapeutic choices. Despite numerous attempts to identify therapeutic aberrations that can be targeted, chemotherapy continues to be the primary systemic treatment for TNBC. It should be noted, however, that multiple studies have shown racial variation in the clinical behaviour of TNBCs and there remains a need to identify alternative, novel driver mutations in our ethnically diverse population, especially actionable mutations that might prove to be potential targets for precision therapy. This study was taken up with the aim to identify distinct targetable genetic alterations in TNBC patients and to report the frequencies of various subtypes.
resultsAmong 353 breast cancer patients, 75 were TNBC, and 10 treatment-naïve TNBC cases were selected for the study. Selected TNBC FFPE (formalin fixed paraffin embedded) tissue samples were subjected to Genomic DNA extraction and whole-exome sequencing followed by bioinformatics analysis for detection of deleterious variants. A total of 812,598 non-synonymous SNPs were identified over the 10 samples. Following application of insilico prediction tools, 275 SNPs were identified. The most frequently mutated genes were OR9G1 and MUC6. Six out of 10 TNBC cases in this study were found to harbour missense variants, c.505 C > T (p.Arg169Cys) and c.335 A > G (p.Tyr112Cys) in the OR9G1 gene. The second most frequently mutated gene in our samples was MUC6 with 5 samples harbouring the variant c.5618 C > A.
conclusionDetection of these variants in six out of 10 cases indicates probable role of these vastly unexplored genes in the pathogenesis of triple-negative breast tumours and warrants further exploration to establish their significance as targetable sites and facilitate drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.